£138.00
Additional information
| Water Retention | Does not cause significant water retention, may actually promote fluid loss due to glycosuria |
|---|---|
| Hepatotoxicity | Low risk of hepatotoxicity |
| Lab Test | May interfere with 1,5-anhydroglucitol (1,5-AG) assay, leading to underestimation of serum 1,5-AG levels and false reports of glycemic control |
| Strength | 100 mg |
| Also known as | Cangliflozin |
| Blood pressure | Can lead to a reduction in blood pressure |
| Trade name | Invokana |
| Storage conditions | Store at room temperature away from moisture and heat |
| Chemical name | (2S,3R,4R,5S,6R)-2-(3-(4-ethoxybenzyl)-4-chlorophenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol |
| Formula | C24H25ClO5 |
| Substance class | SGLT2 inhibitor |
| Main action | Reduces blood glucose by inhibiting sodium-glucose transport protein 2 in the kidneys, leading to glucose excretion through urine |
| Half-life | Approximately 10.6 hours to 13.1 hours |
| Dosage (medical) | Typically 100 mg once daily, may increase to 300 mg based on efficacy and tolerability |
| Dosage (sports) | Not applicable as it is not indicated for performance enhancement |
| Effects | Lowers blood sugar levels in type 2 diabetes patients |
| Side effects | Urinary tract infections, yeast infections, increased urination, risk of lower limb amputation, ketoacidosis, severe dehydration, hypotension |
| Use in sports | None, not used for performance enhancement |
| Manufacturer | Pharmaceutical |
